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The countries of southern Africa are currently at the epicentre 
of the HIV pandemic, and as a consequence of this annual 
tuberculosis (TB) notification rates in these countries have 
increased 2- to 5-fold since 1990.1 An estimated 2.4 million new 
TB cases and 540 000 TB-related deaths occur in sub-Saharan 
Africa annually and this regional epidemic is fuelling a global 
increase in TB incidence of 1% per annum.1,2 In response to this 
HIV-associated TB epidemic the World Health Organization 
(WHO) Committee for Africa declared an African regional 
emergency mandating ‘urgent and extraordinary actions’.3 
   In South Africa some communities have among the highest 
TB incidence rates in the world, with annual TB notification 
rates in some townships in the Western Cape exceeding            
1 000/100 000 in 2003.4 We have more recently described a 
community with TB notification rates approaching 1 500/     
100 000 and rates of over 2 500/100 000 among those aged 
30 - 49 years.5 The majority of this disease burden is HIV-
associated, and even in townships where HIV prevalence rates 
are now stabilising, the sobering reality is that TB incidence 
rates are likely to continue to rise in these communities for 
a further number of years.2,5 This lag between the epidemics 
is because as the HIV epidemic in a community matures, the 
proportion of individuals with advanced immunodeficiency 
continues to increase after HIV prevalence has plateaued. Thus, 
although TB incidence has reached unprecedented levels in 
many communities heavily affected by HIV, further increases 
may occur for some years to come in the absence of further 
effective interventions.
   Although the WHO TB control strategy based on DOTS 
(directly observed treatment, short course) is central to TB 
control efforts globally, it has failed to contain the African TB 
epidemic. It is now clear that although the DOTS strategy is 
necessary, it is insufficient. Additional measures are needed in 
countries with high HIV prevalence. The WHO has therefore 
formulated a strategic framework aimed at functional 
integration of control programmes for TB and HIV/AIDS.6 
It is hoped that a combination of multiple interventions may 
provide a more concerted approach to these epidemics.
   Highly active antiretroviral treatment (HAART) potentially 
has a significant role to play within that strategic framework. 
Since HAART is associated with huge reductions in HIV-
associated morbidity and mortality,7,8 one might anticipate that, 
as access to HAART is scaled up in resource-limited settings, 
this might have a beneficial impact on TB control. In support 
of this supposition, numbers of cohort studies from both high-
income and resource-limited settings have demonstrated that 
HAART reduces TB incidence by 70 - 90% during short-term 
follow-up.9 In a study in Cape Town this benefit was observed 
among patients with a broad range of baseline blood CD4 cell 
counts and WHO clinical stages of disease.10 Paradoxically, 
however, mathematical modelling calculations suggest that 
widespread use of HAART may have very limited impact on 
TB burden.11 Here we explore the reasons why. 
   The proven efficacy of HAART in reducing short-term risk of 
TB in a treatment cohort does not necessarily reflect the likely 
long-term impact of HAART as a TB control intervention at 
the community level. Four additional factors are also of great 
importance.
Long-term risk of incident TB during 
HAART
Antiretroviral treatment (ART) is extremely effective in 
reducing the risk of end stage opportunistic infections such 
as cryptococcal meningitis and pneumocystis pneumonia by 
increasing CD4 cell counts above a safe threshold level. In 
contrast, the risk of TB is increased even among patients with 
high CD4 cell counts and so a safe CD4 cell count threshold 
for minimising risk of TB does not exist. Moreover, although 
HAART substantially restores functional TB-specific immune 
responses, this is almost certainly incomplete in the long term.9 
This is likely to explain why TB incidence rates in the Cape 
Town AIDS cohort have remained elevated at 1  000/100 000/
year after 5 years of HAART.12 Furthermore, in a community-
based treatment cohort in Gugulethu, we estimate that the 
TB incidence of individuals receiving HAART for 3 years 
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remains more than 5-fold greater than the rate among non-
HIV-infected individuals living in the same community (S 
Lawn – unpublished data, 2006). Thus, although HAART is 
associated with a very substantial reduction in risk of TB, the 
effect is nevertheless suboptimal. 
Effective ART coverage
The effective coverage of HAART (reflecting both access and 
adherence to treatment) achieved in a community is obviously 
another important factor affecting the impact of HAART on 
TB control. Although high levels of adherence have been 
demonstrated to be achievable in South African communities,13 
national HAART coverage was estimated at just 10 - 14% in 
June 2005.14 Therefore, at present the low levels of coverage are 
unlikely to have much impact on TB rates at the national level. 
How early HAART is initiated
In high TB prevalence settings, the timing of HAART initiation 
may have a major impact on an individual’s lifetime risk of 
TB. If HAART is initiated late in the course of the disease, 
a significant proportion of HIV-infected individuals will 
have had TB before initiating HAART. For example, in a 
community-based ART service in Gugulethu, patients have a 
median baseline CD4 cell count of < 100 cells/μl;15 51% of them 
have had TB before programme entry, most of which was HIV-
associated (S Lawn – unpublished data, 2006). HAART would 
have to be commenced earlier in the course of disease to have a 
more significant impact on TB burden in these individuals.
   In South Africa utilisation of the WHO 2002    
recommendations16 in the national antiretroviral treatment 
guidelines17 restricts treatment in the public sector to those 
with an AIDS diagnosis or a CD4 cell count < 200 cells/μl. 
In contrast, many other countries in sub-Saharan Africa are 
using the revised 2003 guidelines,18 which recommend earlier 
initiation of therapy. One of the consequences of South African 
policy may be to limit the potential impact of ART on TB-
related morbidity and mortality as is suggested by previous 
mathematical modelling calculations.11  
Increased life expectancy
A further critical variable in determining the impact of HAART 
on TB control is the extent to which this treatment prolongs 
life. We have shown that HAART in Cape Town leads to a 
dramatic decrease in HIV-associated mortality.14 If patients do 
not die then they of course remain at risk of developing TB 
and adding to the community burden of disease. Therefore, 
if HAART were to reduce the annual risk of TB 10-fold, for 
example, and yet prolong life expectancy 10-fold, then there 
would be no net reduction in the individual’s lifetime risk of 
TB during HAART. If risk of TB were reduced 10-fold and life 
expectancy increased 15-fold, however, then lifetime risk of TB 
could paradoxically increase. 
   In conclusion, HIV is driving the current TB epidemic in 
South Africa and rates of HIV-associated TB may continue 
to increase even in communities where HIV prevalence has 
stabilised. HAART roll-out is unlikely to have a substantial 
beneficial impact on this TB epidemic in the foreseeable future 
because: (i) although TB risk reduction is substantial during 
HAART it is incomplete; (ii) patients typically initiate HAART 
with advanced immunodeficiency and this is associated with 
high risk of TB both before and during early HAART; (iii) 
community coverage with HAART is currently low; and (iv) 
life expectancy is increased by HAART, greatly extending 
the period during which patients may develop TB. Sentinel 
communities with good disease surveillance are needed to 
better understand the dynamics of the TB epidemic during 
HAART roll-out. Meanwhile, increased resources are needed 
to strengthen the South African HIV prevention and TB control 
programmes. Additional TB control strategies such as active 
TB case finding and use of isoniazid prophylaxis need to be 
evaluated and where appropriate implemented urgently.
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